Abstract
Purpose
The high diagnostic performance of somatostatin receptor positron emission tomography with computed tomography (PET/CT) in neuroendocrine tumours (NETs) was demonstrated by several articles. However, only some studies evaluated the detection rate (DR) of this imaging method in patients with metastatic NETs and unknown primary tumours (CUP-NETs). Therefore, we aimed to perform a meta-analysis to add evidence-based data in this setting.
Methods
A comprehensive computer literature search of studies listed in PubMed/MEDLINE, EMBASE, and Cochrane library databases through December 2018 and regarding the use of somatostatin receptor PET/CT in patients with CUP-NETs was carried out. Pooled DR of CUP-NETs by using somatostatin receptor PET/CT was calculated. A pooled analysis evaluating the percentage of change of management by using somatostatin receptor PET/CT in these patients was also performed.
Results
Twelve studies on the use of somatostatin receptor PET/CT in detecting CUP-NETs in 383 metastatic patients were included. The meta-analysis of all these studies provided the following DR on a per patient-based analysis: 56% (95% confidence interval (95% CI): 48–63%). Moderate heterogeneity among the selected studies was found (I2 = 50%), whereas a significant publication bias was excluded by Egger’s test (p = 0.45). The most common primary tumour sites were the bowel and the pancreas. A change of management by using somatostatin receptor PET/CT was demonstrated in 20% (95% CI: 10–33%) of patients with CUP-NET.
Conclusions
Somatostatin receptor PET/CT is very useful in detecting CUP-NETs in patients with metastatic disease. More studies on the change of management by using this imaging method in this setting are needed.
Similar content being viewed by others
References
T. Bochtler, H. Loffler, A. Kramer, Diagnosis and management of metastatic neoplasms with unknown primary. Semin. Diagn. Pathol. 35(3), 199–206 (2018). https://doi.org/10.1053/j.semdp.2017.11.013
K. Alexandraki, A. Angelousi, G. Boutzios, G. Kyriakopoulos, D. Rontogianni, G. Kaltsas, Management of neuroendocrine tumors of unknown primary. Rev. Endocr. Metab. Disord. 18(4), 423–431 (2017). https://doi.org/10.1007/s11154-017-9437-9
B. Givi, S.J. Pommier, A.K. Thompson, B.S. Diggs, R.F. Pommier, Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140(6), 891–897 (2006). https://doi.org/10.1016/j.surg.2006.07.033. discussion 897-898
M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska, W.J.G. Oyen, A. Chiti, F. Giammarile, A. Sundin, S. Fanti, Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur. J. Nucl. Med. Mol. imaging 44(9), 1588–1601 (2017). https://doi.org/10.1007/s00259-017-3728-y
G. Treglia, R. Sadeghi, A. Del Sole, L. Giovanella, Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review. Clin. Transl. Oncol. 16(9), 770–775 (2014). https://doi.org/10.1007/s12094-014-1168-8
G. Treglia, A.S. Kroiss, A. Piccardo, F. Lococo, P. Santhanam, A. Imperiale, Role of positron emission tomography in thyroid and neuroendocrine tumors. Minerva Endocrinol. 43(3), 341–355 (2018). https://doi.org/10.23736/s0391-1977.17.02742-0
S. Singh, R. Poon, R. Wong, U. Metser, 68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin. Nucl. Med. 43(11), 802–810 (2018). https://doi.org/10.1097/rlu.0000000000002276
M. Barrio, J. Czernin, S. Fanti, V. Ambrosini, I. Binse, L. Du, M. Eiber, K. Herrmann, W.P. Fendler, The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J. Nucl. Med. 58(5), 756–761 (2017). https://doi.org/10.2967/jnumed.116.185587
S.A. Deppen, J. Blume, A.J. Bobbey, C. Shah, M.M. Graham, P. Lee, D. Delbeke, R.C. Walker, 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57(6), 872–878 (2016). https://doi.org/10.2967/jnumed.115.165803
H. Geijer, L.H. Breimer, Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. imaging 40(11), 1770–1780 (2013). https://doi.org/10.1007/s00259-013-2482-z
G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012). https://doi.org/10.1007/s12020-012-9631-1
P. Santhanam, S. Chandramahanti, A. Kroiss, R. Yu, P. Ruszniewski, R. Kumar, D. Taieb, Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Eur. J. Nucl. Med. Mol. imaging 42(7), 1144–1155 (2015). https://doi.org/10.1007/s00259-015-3027-4
M.D.F. McInnes, D. Moher, B.D. Thombs, T.A. McGrath, P.M. Bossuyt, T. Clifford, J.F. Cohen, J.J. Deeks, C. Gatsonis, L. Hooft, H.A. Hunt, C.J. Hyde, D.A. Korevaar, M.M.G. Leeflang, P. Macaskill, J.B. Reitsma, R. Rodin, A.W.S. Rutjes, J.P. Salameh, A. Stevens, Y. Takwoingi, M. Tonelli, L. Weeks, P. Whiting, B.H. Willis, Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 319(4), 388–396 (2018). https://doi.org/10.1001/jama.2017.19163
I. Simera, D. Moher, J. Hoey, K.F. Schulz, D.G. Altman, A catalogue of reporting guidelines for health research. Eur. J. Clin. Investig. 40(1), 35–53 (2010). https://doi.org/10.1111/j.1365-2362.2009.02234.x
R. Sadeghi, G. Treglia, Systematic reviews and meta-analyses of diagnostic studies: a practical guideline. Clin. Transl. Imaging 5(2), 83–87 (2017). https://doi.org/10.1007/s40336-016-0219-2
P.F. Whiting, A.W. Rutjes, M.E. Westwood, S. Mallett, J.J. Deeks, J.B. Reitsma, M.M. Leeflang, J.A. Sterne, P.M. Bossuyt, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155(8), 529–536 (2011). https://doi.org/10.7326/0003-4819-155-8-201110180-00009
J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002). https://doi.org/10.1002/sim.1186
R.M. Harbord, M. Egger, J.A. Sterne, A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 25(20), 3443–3457 (2006). https://doi.org/10.1002/sim.2380
N. Sampathirao, S. Basu, MIB-1 index-stratified assessment of dual-tracer PET/CT with (68)Ga-DOTATATE and (18)F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. J. Nucl. Med. Technol. 45(1), 34–41 (2017). https://doi.org/10.2967/jnmt.116.185777
Y. Menda, T.M. O’Dorisio, J.R. Howe, M. Schultz, J.S. Dillon, D. Dick, G.L. Watkins, T. Ginader, D.L. Bushnell, J.J. Sunderland, G.K.D. Zamba, M. Graham, M.S. O’Dorisio, Localization of unknown primary site with (68)Ga-DOTATOC PET/CT in patients with metastatic neuroendocrine tumor. J. Nucl. Med. 58(7), 1054–1057 (2017). https://doi.org/10.2967/jnumed.116.180984
P.M. Kazmierczak, A. Rominger, V. Wenter, C. Spitzweg, C. Auernhammer, M.K. Angele, C. Rist, C.C. Cyran, The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Eur. Radiol. 27(4), 1676–1684 (2017). https://doi.org/10.1007/s00330-016-4475-3
S.M. Sadowski, V. Neychev, C. Millo, J. Shih, N. Nilubol, P. Herscovitch, K. Pacak, S.J. Marx, E. Kebebew, Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J. Clin. Oncol. 34(6), 588–596 (2016). https://doi.org/10.1200/jco.2015.64.0987
A. Pruthi, P. Pankaj, R. Verma, A. Jain, E.S. Belho, H. Mahajan, Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J. Gastrointest. Oncol. 7(3), 449–461 (2016). https://doi.org/10.21037/jgo.2016.01.06
Y. Nakamoto, K. Sano, T. Ishimori, M. Ueda, T. Temma, H. Saji, K. Togashi, Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors. Ann. Nucl. Med. 29(6), 512–518 (2015). https://doi.org/10.1007/s12149-015-0973-7
O. Alonso, M. Rodriguez-Taroco, E. Savio, C. Bentancourt, J.P. Gambini, H. Engler, 68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann. Nucl. Med. 28(7), 638–645 (2014). https://doi.org/10.1007/s12149-014-0856-3
N.F. Schreiter, A.M. Bartels, V. Froeling, I. Steffen, U.F. Pape, A. Beck, B. Hamm, W. Brenner, R. Rottgen, Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol. Oncol. 48(4), 339–347 (2014). https://doi.org/10.2478/raon-2014-0018
T.H. Tan, B.N. Lee, S.Z. Hassan, Diagnostic value of (68)Ga-DOTATATE PET/CT in liver metastases of neuroendocrine tumours of unknown origin. Nucl. Med. Mol. imaging 48(3), 212–215 (2014). https://doi.org/10.1007/s13139-013-0258-9
N. Naswa, P. Sharma, A. Kumar, R. Soundararajan, R. Kumar, A. Malhotra, A.C. Ammini, C. Bal, (6)(8)Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin. Nucl. Med. 37(3), 245–251 (2012). https://doi.org/10.1097/RLU.0b013e31823ea730
G. Lapinska, M. Bryszewska, A. Fijolek-Warszewska, I. Kozlowicz-Gudzinska, P. Ochman, A. Sackiewicz-Slaby, The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl. Med. Rev. Cent. East. Eur. 14(1), 16–20 (2011)
V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, R.P. Baum, Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur. J. Nucl. Med. Mol. imaging 37(1), 67–77 (2010). https://doi.org/10.1007/s00259-009-1205-y
S. Gabriel, P. Garrigue, L. Dahan, F. Castinetti, F. Sebag, K. Baumstark, C. Archange, A. Jha, K. Pacak, B. Guillet, D. Taieb, Prospective evaluation of (68) Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clin. Endocrinol. (2018). https://doi.org/10.1111/cen.13745
S.H. Chen, Y.C. Chang, T.L. Hwang, J.S. Chen, W.C. Chou, C.H. Hsieh, T.S. Yeh, J.T. Hsu, C.N. Yeh, J.H. Tseng, T.C. Chen, T.C. Yen, 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan. J. Formos. Med. Assoc. 117(6), 480–487 (2018). https://doi.org/10.1016/j.jfma.2017.07.007
A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak, S.J. Marx, L. Yang, P. Nockel, J. Shell, P. Green, X.M. Keutgen, D. Patel, N. Nilubol, E. Kebebew, Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur. J. Endocrinol. 176(5), 575–582 (2017). https://doi.org/10.1530/eje-16-1079
P. Thapa, R. Ranade, V. Ostwal, S.V. Shrikhande, M. Goel, S. Basu, Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl. Med. Commun. 37(10), 1030–1037 (2016). https://doi.org/10.1097/mnm.0000000000000547
J. Kunikowska, D. Pawlak, A. Kolasa, R. Mikolajczak, L. Krolicki, A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin. Nucl. Med. 39(10), 855–861 (2014). https://doi.org/10.1097/rlu.0000000000000533
M. Pavel, D. O’Toole, F. Costa, J. Capdevila, D. Gross, R. Kianmanesh, E. Krenning, U. Knigge, R. Salazar, U.F. Pape, K. Oberg, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172–185 (2016). https://doi.org/10.1159/000443167
A. Polish, M.T. Vergo, M. Agulnik, Management of neuroendocrine tumors of unknown origin. J. Natl. Compr. Cancer Netw. 9(12), 1397–1402 (2011). quiz 1403
M.H. Shah, W.S. Goldner, T.R. Halfdanarson, E. Bergsland, J.D. Berlin, D. Halperin, J. Chan, M.H. Kulke, A.B. Benson 3rd, L.S. Blaszkowsky, J. Eads, P.F. Engstrom, P. Fanta, T. Giordano, J. He, M.J. Heslin, G.P. Kalemkerian, F. Kandeel, S.A. Khan, W.Z. Kidwai, P.L. Kunz, B.W. Kuvshinoff 2nd, C. Lieu, V.G. Pillarisetty, L. Saltz, J.A. Sosa, J.R. Strosberg, C.A. Sussman, N.A. Trikalinos, N.A. Uboha, J. Whisenant, T. Wong, J.C. Yao, J.L. Burns, N. Ogba, G. Zuccarino-Catania, NCCN Guidelines insights: neuroendocrine and adrenal tumors, Version 2.2018. J. Natl. Compr. Cancer Netw. 16(6), 693–702 (2018). https://doi.org/10.6004/jnccn.2018.0056
V. Rufini, G. Treglia, F. Montravers, A. Giordano, Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin. Transl. Imaging 1, 111–122 (2013)
A. Imperiale, E. Rust, S. Gabriel, J. Detour, B. Goichot, B. Duclos, J.E. Kurtz, P. Bachellier, I.J. Namer, D. Taieb, 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J. Nucl. Med. 55(3), 367–372 (2014). https://doi.org/10.2967/jnumed.113.126896
Acknowledgements
We thank all the staff of the Clinical Trial Unit of Ente Ospedaliero Cantonale for their support. The Clinical Trail Unit of Ente Ospedaliero Cantonale was in charge of literature search, statistical analysis and manuscript writing.
Funding
This study was performed through a funded activity of the Clinical Trial Unit of Ente Ospedaliero Cantonale.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
*Sara De Dosso and Giorgio Treglia share the first authorship.
**Piercarlo Saletti and Luca Giovanella share the last authorship.
Rights and permissions
About this article
Cite this article
De Dosso, S., Treglia, G., Pascale, M. et al. Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis. Endocrine 64, 456–468 (2019). https://doi.org/10.1007/s12020-019-01934-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01934-9